During April 25th to 28th, 2025, the 17th National Academic Conference on Radiopharmaceuticals and Labeled Compounds was grandly held in the ancient capital city of Xi'an. This conference was sponsored by the Nuclear Chemistry and Radiochemistry Branch of the Chinese Nuclear Society, undertaken by Beijing Normal University, and jointly co-organized by the Radiopharmaceuticals Branch of the Chinese Nuclear Society, China Isotope & Radiation Corporation, the Nuclear Medicine Branch of the Chinese Medical Association, the Isotope Branch of the Chinese Nuclear Society, etc. It attracted hundreds of experts and scholars from universities, scientific research institutions, medical institutions and enterprises to gather together. Focusing on the theme of "Innovation and Clinical Transformation of Radiopharmaceuticals", experts in this field jointly discussed the technological breakthroughs and industrial application in the field of radiopharmaceuticals.
The opening ceremony of the conference was presided over by Professor Huabei Zhang from Beijing Normal University. Leaders such as Youqian Ding (Chairman of the Chinese Nuclear Society and Radiochemistry), Xiaoli Wang (Inspector of the Shanxi Association for Science and Technology), and Keli Gao (Deputy Secretary General of the Chinese Nuclear Society) delivered speeches. Chairman Youqian Ding pointed out: "At present, we are standing at a juncture full of opportunities and challenges. It requires us to gather more new forces, promote the coordinated progress of basic research and industry, and drive the high-quality and high-level development of nuclear medicine in our country."
This conference set up one main forum, two special sub-forums and a Young Scientists Forum. In-depth discussions were carried out around six major topics, including the research and development of medical radionuclides, the research and development of radiopharmaceuticals, the quality control and management of radiopharmaceuticals, the biological evaluation and application of radiopharmaceuticals, the preparation and application of labeled compounds, and the design, preparation and application of multimodal molecular probes.
At the conference, Director Zhi Yang from Peking University Cancer Hospital comprehensively reviewed the progress of clinical research on radiopharmaceuticals. The team led by Zhen Cheng from Shanghai Institute of Materia Medica shared the innovative development of radiopharmaceuticals. Professor Zhibo Liu from Peking University looked ahead to the continued exploration of radiopharmaceutical research. Director Hua Zhu from Peking University Cancer Hospital discussed the research and development and clinical transformation of radionuclide probes for key sugar targets. Professor Xianzhong Zhang from Peking Union Medical College Hospital demonstrated the research and innovative application of small-molecule radiopharmaceuticals. Researcher Jianguo Lin from Jiangsu Institute of Nuclear Medicine introduced how intelligent radionuclide molecular probes achieve precise drug delivery.
As the executive director of the Second Council of the Radiopharmaceuticals Branch of the Chinese Nuclear Society, Ms. Haixia Jiang, also the Chief Scientist of United Well, said in an interview: "This conference closely adheres to the strategic needs of the country, and the synergistic effect of industry, university and research is remarkable. In particular, the breakthrough in the integrated diagnosis and treatment technology has provided a new paradigm for precise tumor treatment. The targeted α radionuclide drug project that United Well is promoting is also highly consistent with the concept of 'innovation-driven' advocated by the conference. We look forward to accelerating technology transformation through the platform of this conference to benefit more patients."
